Vinblastine Sulphate Injection – Cytoblastin contains Vinblastine Sulphate, a vinca alkaloid antineoplastic medicine used in combination chemotherapy for various hematological malignancies and solid tumors.

Vinblastine acts by binding to tubulin and inhibiting microtubule formation, thereby disrupting mitosis and preventing the division and proliferation of rapidly growing cancer cells. It is administered under the supervision of qualified healthcare professionals as part of an appropriate chemotherapy regimen.

Cytoblastin may be incorporated into treatment protocols for Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer, breast cancer, Kaposi sarcoma, and other selected malignancies, depending on the patient’s diagnosis and treatment protocol.

What is Vinblastine Sulphate?

Vinblastine Sulphate is a vinca alkaloid and cytotoxic antineoplastic agent. It interferes with microtubule formation, which disrupts cell division and contributes to the inhibition of cancer-cell growth.

Vinblastine is generally used as part of combination chemotherapy and requires careful dosing and monitoring by an oncology specialist.

Benefits / Uses

Cytoblastin may be used in appropriate chemotherapy protocols for:

• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Testicular cancer
• Breast cancer
• Kaposi sarcoma
• Other selected hematological malignancies
• Selected solid tumors

The specific indication and combination of medicines depend on the patient’s diagnosis and the treating oncologist’s protocol.

Dosage Guidelines

Vinblastine Sulphate Injection must be administered only by qualified healthcare professionals according to the prescribed chemotherapy regimen.

• The dose is individualized based on the indication, body surface area, blood counts, liver function, and treatment protocol.
• It is administered by the intravenous route.
• Complete blood counts should be monitored regularly because myelosuppression is an important dose-limiting toxicity.
• Dose modification or treatment interruption may be required depending on blood counts and other toxicities.
• Liver function and other relevant clinical parameters may also require monitoring.
• Vinblastine must never be administered intrathecally, as this can cause fatal toxicity.

The exact dose, frequency, dilution, and administration procedure should follow the approved prescribing information and specialist oncology protocol.

Wholesale & Supply

Cytoblastin – Vinblastine Sulphate Injection can be supplied to hospitals, oncology centers, pharmaceutical distributors, wholesalers, and international healthcare markets, subject to applicable regulatory requirements.

Bulk buyers can request:

• Available strengths and presentations
• Packaging configuration
• Minimum order quantity
• Production and supply capacity
• Certificate of Analysis (CoA)
• Product documentation
• Regulatory and export documents

Buying Online

Vinblastine Sulphate is a prescription cytotoxic chemotherapy medicine and should only be procured through authorized pharmaceutical suppliers and administered in an appropriate healthcare setting.

Hospitals, licensed distributors, and healthcare procurement organizations can contact the supplier for product availability, commercial quotations, and applicable documentation.

Reviews

Individual responses to Vinblastine-based chemotherapy vary according to cancer type, disease stage, treatment combination, previous therapies, and patient-specific factors. Treatment decisions should therefore be based on the treating oncologist’s clinical assessment rather than individual product reviews.

Quality Assurance

Cytoblastin should be manufactured and handled according to applicable pharmaceutical quality requirements. Quality-control testing for injectable products may include:

• Identification and assay
• Purity and related substances
• Sterility
• Bacterial endotoxins
• Particulate matter
• pH and appearance
• Stability testing
• Container-closure integrity

Product-specific quality and regulatory documentation can be provided upon request, where applicable.

Frequently Asked Questions

What is Cytoblastin used for?

Cytoblastin contains Vinblastine Sulphate and may be used in chemotherapy protocols for Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer, breast cancer, Kaposi sarcoma, and other selected malignancies.

What type of medicine is Vinblastine Sulphate?

Vinblastine Sulphate is a vinca alkaloid and cytotoxic antineoplastic medicine that inhibits microtubule formation and interferes with cancer-cell division.

How is Cytoblastin administered?

Cytoblastin is administered intravenously by qualified healthcare professionals according to the prescribed chemotherapy protocol.

Can Vinblastine be administered intrathecally?

No. Vinblastine must never be administered intrathecally, because this can result in fatal toxicity.

What are the important side effects of Vinblastine?

Potential adverse effects include bone-marrow suppression, leukopenia, anemia, thrombocytopenia, constipation, nausea, vomiting, hair loss, and injection-site complications. The severity depends on the dose and treatment regimen.

Does Vinblastine require blood-count monitoring?

Yes. Regular blood-count monitoring is important because myelosuppression is a major toxicity and may require dose adjustment or treatment interruption.

Conclusion

Cytoblastin – Vinblastine Sulphate Injection is a vinca alkaloid chemotherapy medicine that inhibits microtubule formation and cancer-cell division. It is used in selected hematological malignancies and solid tumors, generally as part of combination chemotherapy. Because it can cause significant myelosuppression and other toxicities, its administration and monitoring should be performed under specialist oncology supervision.